Lakshmanan Rajesh, Maulik Nilanjana
Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health, Farmington, CT 06030, USA.
Can J Physiol Pharmacol. 2018 Sep;96(9):869-878. doi: 10.1139/cjpp-2018-0225. Epub 2018 Aug 23.
The time and dosage form of graphene derivatives have been found to determine therapeutic and toxic windows in several cell lines and preclinical models. The enhanced biological action of graphene derivatives is made possible by altering the chemistry of native materials via surface conjugation, or by changing the oxidation state. The high level of chemical reactivity vested in the planar structure of graphene can be used to load various drugs and biomolecules with maximum radical scavenging effect. The integration of graphene and polymers brings electrical conductivity to scaffolds, making them ideal for cardiac or neuronal tissue engineering. Drawbacks associated with graphene-based materials for biomedical applications include defect-free graphene formation and heteroatom contamination during synthesis process; reduced availability of sp hybridized carbon centers due to serum proteins masking; and poor availability of data pertaining to in vivo clearance of graphene-based formulations. Personalized medicine is an emerging area of alternative treatments, which in combination with graphene-based nanobiomaterials, has revolutionary potential for the development of individualized nanocarriers to treat highly challenging diseases.
已发现石墨烯衍生物的时间和剂型可在多种细胞系和临床前模型中确定治疗窗口和毒性窗口。通过表面共轭改变天然材料的化学性质,或改变氧化态,可使石墨烯衍生物的生物活性增强。石墨烯平面结构所具有的高化学反应活性可用于负载各种药物和生物分子,以发挥最大的自由基清除作用。石墨烯与聚合物的结合赋予支架导电性,使其成为心脏或神经组织工程的理想材料。用于生物医学应用的基于石墨烯的材料存在的缺点包括:合成过程中无缺陷石墨烯的形成和杂原子污染;由于血清蛋白掩盖,sp杂化碳中心的可用性降低;以及关于基于石墨烯的制剂体内清除的数据可用性较差。个性化医疗是替代治疗的一个新兴领域,与基于石墨烯的纳米生物材料相结合,在开发用于治疗极具挑战性疾病的个性化纳米载体方面具有革命性潜力。